InsiderDB
Sign inStart free trial

Rep. Robert P. Bresnahan, Jr. sold Biogen (BIIB)

Rep. Robert P. Bresnahan, Jr. (R-PA-8) · $1K–$15K · traded Apr 8, 2025

Transaction
Sold
Amount
$1K–$15K
Owner
Not stated
Traded
Apr 8, 2025
Disclosed
May 8, 2025
Days to disclose
30
Asset type
Stock
As filed
Biogen Inc. - Common Stock
Industry
Drug Manufacturers - General · Healthcare
Official filing ↗All of Bresnahan's tradesAll Congress trades in BIIB

Other trades in this filing

All of Bresnahan's trades →

Recent Congress trades in BIIB

Company context for BIIB

Recent records for the company. These may have been published before or after this trade; compare the dates before drawing a connection.

  1. BIIBFinancial report·SEC EDGAR

    BIIB: 10-Q financial filing

    Filed 10-Q for an event or period dated 2026-09-30. Read the company report for its disclosures.

    Public: Oct 28, 2026, 6:23 AM EDTEvent / period: Sep 30, 2026Original source ↗

    1 congressional household disclosed purchases in the past 90 days. See the trades

  2. BIIBCompany announcement·SEC EDGAR

    BIIB: Financial results

    Filed 8-K for an event or period dated 2026-10-28. Financial results.

    Public: Oct 28, 2026, 6:07 AM EDTEvent / period: Oct 28, 2026Original source ↗

    1 congressional household disclosed purchases in the past 90 days. See the trades

  3. BIIBLobbying report·Lobbying disclosures

    BIIB: third_quarter 2026 lobbying report

    Issues related to Alzheimer's Disease and treatment. Amyotrophic lateral sclerosis (ALS), Lou Gehrigs Disease and treatment and Lupus. Issues related to the budget and appropriations process Issues related to rare diseases and treatment. Issues related to Mental Health treatment. Issues related to maternal health. Issues related to the budget and appropriations process

    Public: Oct 20, 2026, 11:09 PM EDTOriginal source ↗

    1 congressional household disclosed purchases in the past 90 days. See the trades

From a periodic transaction report filed under the STOCK Act. Amounts are the ranges members report. Nothing here is investment advice.